Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Up 1.6%

UTHR opened at $553.14 on Wednesday. The firm has a market cap of $23.48 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 1.77 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a fifty day moving average price of $569.08 and a 200-day moving average price of $520.18.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $6.63 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Leuthold Group LLC boosted its stake in shares of United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. Tobam boosted its stake in shares of United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares during the last quarter. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $1,059,000. Finally, SG Americas Securities LLC boosted its stake in shares of United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock worth $13,136,000 after buying an additional 12,663 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.